Pierre Gurdjian - UCB SA Independent Director
UCBJY Stock | USD 58.22 1.22 2.14% |
Director
Mr. Pierre L. Gurdjian has served as Independent NonExecutive Vice Chairman of the Board of UCB S.A. since April 27, 2017. Prior to that, he has served as NonExecutive Independent Director at UCB S.A. since April 28, 2016. He is Member of the Governance, Nomination and Compensation Committee at the Company as of 2016. He is a senior professional in the field of Philanthropy and Education. He is Philanthropy Partner of the RVVZ Foundation since the beginning of 2015, and President of the Board of Directors of the Universite Libre de Bruxelles, effective January 2016. Before he was a Senior Partner at McKinsey and Co. where he was active for nearly three decades. He led the Belgian office between 2005 and 2012. He was President of the Board of the Universite Libre de Bruxelles. He holds a Masters of Business Administration degree from Harvard Business School, and a Bachelors degree in Engineering from Vrije Universiteit Brussel. since 2017.
Age | 57 |
Tenure | 7 years |
Phone | 32 2 559 99 99 |
Web | https://www.ucb.com |
UCB SA Management Efficiency
The company has return on total asset (ROA) of 0.0468 % which means that it generated a profit of $0.0468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1069 %, meaning that it generated $0.1069 on every $100 dollars invested by stockholders. UCB SA's management efficiency ratios could be used to measure how well UCB SA manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | DIRECTOR Age | ||
Liselotte Hyveled | Novo Nordisk AS | 51 | |
Elizabeth Corley | Pearson PLC ADR | 63 | |
Kasim Kutay | Novo Nordisk AS | 55 | |
Stefan Loren | Moderna | 50 | |
Elaine Ullian | Vertex Pharmaceuticals | 69 | |
Charles Baker | Regeneron Pharmaceuticals | 84 | |
George Sing | Regeneron Pharmaceuticals | 68 | |
Margaret McGlynn | Vertex Pharmaceuticals | 58 | |
Thomas Koestler | Novo Nordisk AS | 63 | |
Lloyd Carney | Vertex Pharmaceuticals | 56 | |
Sally Johnson | Pearson PLC ADR | 51 | |
Josh Lewis | Pearson PLC ADR | 56 | |
Alfred Gilman | Regeneron Pharmaceuticals | 72 | |
Michael Lynton | Pearson PLC ADR | 61 | |
Anne Kverneland | Novo Nordisk AS | 64 | |
Mary Szela | Novo Nordisk AS | 52 | |
Donald Williams | Moderna | 55 | |
Graeme Pitkethly | Pearson PLC ADR | 54 | |
Bruce Sachs | Vertex Pharmaceuticals | 58 | |
Marc TessierLavigne | Regeneron Pharmaceuticals | 58 | |
Mette Jensen | Novo Nordisk AS | 45 |
Management Performance
Return On Equity | 0.11 | |||
Return On Asset | 0.0468 |
UCB SA ADR Leadership Team
Elected by the shareholders, the UCB SA's board of directors comprises two types of representatives: UCB SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of UCB. The board's role is to monitor UCB SA's management team and ensure that shareholders' interests are well served. UCB SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, UCB SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
Pascale Richetta, Executive Vice President Bone Patient Value Unit Head, Member of the Executive Committee | ||
Detlef Thielgen, CFO and Executive VP | ||
Kay Davies, Independent Director | ||
Dirk Teuwen, VP Corporate Societal Responsibility | ||
Anna Richo, Executive VP and General Counsel | ||
Viviane Monges, Independent Non-Executive Director | ||
Gerhard Mayr, Non-Executive Chairman of the Board | ||
Cyril Janssen, Director | ||
Caroline Vancoillie, Chief Functions | ||
Cedric Rijckevorsel, Director | ||
JeanChristophe Tellier, Chairman of the Executive Committee, CEO | ||
Arnoud Calesberg, Non-Executive Director | ||
Mark McDade, COO and Executive VP | ||
Xavier Michel, Vice President and Secretary General | ||
Dhavalkumar Patel, Executive Vice President Chief Scientific Officer, Member of the Executive Committee | ||
Bharat Tewarie, Executive Vice President Chief Marketing Officer | ||
Roch Doliveux, Chairman of the Executive Committee, CEO, Executive Director | ||
Norman Ornstein, Non-Executive Independent Director | ||
Jeff Wren, Executive Vice President Neurology – Patient Value Unit Head | ||
JeanPierre Kinet, Non-Executive Independent Director | ||
Antje Witte, VP of Investor Relations | ||
Alice Dautry, Independent Director | ||
Sandrine CFA, Ex CFO | ||
Harriet Edelman, Non-Executive Independent Director | ||
Ulf Wiinberg, Independent Director | ||
William Silbey, Exec Counsel | ||
Thomas McKillop, Non-Executive Independent Director | ||
Charl Zyl, Executive Vice President Head of Patient Value Operations, Member of the Executive Committee | ||
France Nivelle, VP Global Communication | ||
Fabrice Enderlin, Executive Vice President - Human Resources & Communication, Member of the Executive Committee | ||
Pierre Gurdjian, Independent Director | ||
Ismail Kola, Chief Scientific Officer, Head of New Medicines Patient Value Unit and Executive VP | ||
Emmanuel Caeymaex, Executive Vice President Immunology - Patient Value Unit Head | ||
Evelyn Bergendal, Non-Executive Vice Chairwoman of the Board | ||
Iris LoewFriedrich, Executive Vice President Chief Medical Officer | ||
CharlesAntoine Janssen, Non-Executive Director | ||
Pr LowFriedrich, Chief VP | ||
Kirsten LundJurgensen, Ex Solutions | ||
Albrecht Graeve, Non-Executive Independent Director | ||
JeanLuc Fleurial, Executive Vice President Chief Talent Officer, Member of the Executive Committee | ||
Alexander Moscho, Executive Vice President Chief Strategy Officer, Member of the Executive Committee |
UCB Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is UCB SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.11 | |||
Return On Asset | 0.0468 | |||
Profit Margin | 0.15 % | |||
Operating Margin | 0.19 % | |||
Current Valuation | 16.62 B | |||
Shares Outstanding | 379.92 M | |||
Price To Earning | 17.55 X | |||
Price To Book | 1.55 X | |||
Price To Sales | 2.54 X | |||
Revenue | 5.78 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.ABBV | AbbVie Inc | |
HBI | Hanesbrands | |
MIDU | Direxion Daily Mid |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UCB SA ADR. Also, note that the market value of any Company could be tightly coupled with the direction of predictive economic indicators such as signals in inflation. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Complementary Tools for UCB Pink Sheet analysis
When running UCB SA's price analysis, check to measure UCB SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy UCB SA is operating at the current time. Most of UCB SA's value examination focuses on studying past and present price action to predict the probability of UCB SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move UCB SA's price. Additionally, you may evaluate how the addition of UCB SA to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Transaction History View history of all your transactions and understand their impact on performance | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |